Citations

Clear

2 citation(s) found for "Stephens, Richard".

Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis and Prior Mediastinal Radiation: A Meta-Analysis of Short-Term and 1-Year Outcomes
Elbenawi, Hossam , Mostafa, N., Dahik, Buseyna, Botros, Michael, Eisa, Mahmoud , Zreigh, Sofian , Kalaiger, Abdul M., Almaadawy, Omar , Youssef, Mohammed, Zaaya, Morad, Stephens, R. E., Ghanim, Mostafa, Lin, Chien‐Jung, Elgendy, I S L A M, Goldsweig, Andrew M., Mostafa, Naydeen , Stephens, Richard, Kalaiger, Abdul Mukhtadir , Abdelgalil, Mahmoud Shaaban , Hamed, Belal Mohamed , Botros, Michael, Stephens, Richard, Elgendy, Islam Y. , Goldsweig, Andrew M.

Mayo Clinic

Cardiology in Review | March 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001263 | PMID 41913240 Get It

Mediastinal radiation potentiates aortic stenosis and complicates its treatment. We compared the short and midterm-outcomes with transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with prior mediastinal radiation. Electronic databases were searched from inception through December 2024. Dichotomous outcomes were pooled as risk ratios (RRs), and continuous outcomes were pooled as mean differences (MDs) with respective 95% confidence intervals (CIs). Six observational studies were identified, including 2458 TAVR patients and 1873 SAVR patients. In the short-term, TAVR was associated with lower rate of mortality (RR: 0.54; 95% CI: 0.34–0.88), atrial fibrillation (RR: 0.31; 95% CI: 0.15–0.65), acute kidney injury (RR: 0.75; 95% CI: 0.59–0.95), bleeding (RR: 0.37, 95% CI: 0.33–0.42), and shorter length of hospital stay (MD: −4.30; 95% CI: −5.45 to −3.15). One-year mortality was comparable between the 2 groups (RR: 1.04; 95% CI: 0.50–2.13). This meta-analysis of observational studies of patients with prior mediastinal radiation demonstrated that TAVR was associated with better short-term outcomes compared to SAVR. While 1-year mortality appeared similar between the 2 interventions, this finding should be interpreted with caution. However, randomized controlled trials are needed to validate these findings.
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
Sargent, Daniel J. , Köhne, Claus Henning, Sanoff, Hanna K. , Bot, Brian M. , Seymour, Michel , Gramont, Aimery de , Porschen, R, Saltz, Leonard B. , Rougier, Philippe, Tournigand, C., Douillard, Jean‐Yves , Grothey, Axel, Goldberg, Richard M. , Stephens, Richard J. , Sargent, Daniel J , Saltz, Leonard , Seymour, Matthew T , Sanoff, Hanna

Mayo Clinic

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 12 | Pages: 1948-1955

10.1200/jco.2008.20.2879 | PMID 19255311 Get It

PurposePerformance status (PS) is a prognostic factor in patients with metastatic colorectal cancer. Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain.Patients and MethodsIndividual data from 6,286 patients (509 PS2 patients) from nine clinical trials were used to compare treatment efficacy by PS. Progression-free survival (PFS), grade ≥ 3 adverse events, 60-day all-cause mortality, overall survival (OS), and response rate (RR) were explored in the full set of nine trials and in the five trials comparing first-line monotherapy with combination therapy.ResultsCompared with patients with PS of 0 or 1, PS2 patients had significantly higher rates of grade ≥ 3 nausea (8.5% v 16.4%, respectively; P < .0001) and vomiting (7.6% v 11.9%, respectively; P = .006) and 60-day all-cause mortality (2.8% v 12.0%, respectively; P < .0001). PS2 was prognostic for PFS (hazard ratio [HR] = 1.52; P < .0001; median PFS, 7.6 months for PS 0 or 1 v 4.9 months for PS2), OS (HR = 2.18; P < .0001; median OS, 17.3 months for PS 0 or 1 v 8.5 months for PS2), and RR (odds ratio = 0.61; P < .0001; 43.8% for PS 0 or 1 v 32.0% for PS2). The relative benefit and toxicity of experimental versus control treatment and monotherapy versus combination therapy were not different in PS 0 or 1 patients versus PS2 patients.ConclusionIn clinical trials, PS2 patients derive similar benefit from superior treatment as patients with PS of 0 to 1 but with an increased risk of toxicities and 12% 60-day mortality. Although current treatment provides benefit, new approaches are required to approach 1-year median survival for PS2 patients.